News Image

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.

By Mill Chart

Last update: Feb 13, 2024

Our stock screener has spotted EXELIXIS INC (NASDAQ:EXEL) as an undervalued stock with solid fundamentals. NASDAQ:EXEL shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.

ChartMill's Evaluation of Valuation

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:EXEL scores a 7 out of 10:

  • Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.77% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 97.12% of the companies listed in the same industry.
  • 94.75% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
  • 96.79% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 45.38% in the coming years.

Understanding NASDAQ:EXEL's Profitability

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:EXEL has achieved a 7:

  • EXEL has a better Return On Assets (7.06%) than 96.62% of its industry peers.
  • With an excellent Return On Equity value of 9.18%, EXEL belongs to the best of the industry, outperforming 95.60% of the companies in the same industry.
  • EXEL's Return On Invested Capital of 5.31% is amongst the best of the industry. EXEL outperforms 95.43% of its industry peers.
  • With an excellent Profit Margin value of 11.35%, EXEL belongs to the best of the industry, outperforming 96.28% of the companies in the same industry.
  • EXEL has a better Operating Margin (9.34%) than 95.26% of its industry peers.
  • EXEL's Gross Margin of 96.04% is amongst the best of the industry. EXEL outperforms 95.77% of its industry peers.

Deciphering NASDAQ:EXEL's Health Rating

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:EXEL, the assigned 7 reflects its health status:

  • An Altman-Z score of 6.58 indicates that EXEL is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 6.58, EXEL belongs to the best of the industry, outperforming 80.20% of the companies in the same industry.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 3.34 indicates that EXEL has no problem at all paying its short term obligations.
  • A Quick Ratio of 3.30 indicates that EXEL has no problem at all paying its short term obligations.

Understanding NASDAQ:EXEL's Growth

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:EXEL scores a 6 out of 10:

  • The Earnings Per Share has grown by an impressive 22.81% over the past year.
  • EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.60%.
  • Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 16.47% on average per year.
  • Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 28.61% on average per year.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of EXEL

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

EXELIXIS INC

NASDAQ:EXEL (4/24/2024, 2:19:37 PM)

23.685

+0.39 (+1.7%)

EXEL News

News Image9 hours ago - ChartmillTechnical Signals Point to a Possible Breakout for EXELIXIS INC.

EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

News Image10 hours ago - ChartmillNASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

News Image8 days ago - Exelixis, Inc.Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
News Imagea month ago - InvestorPlace3 Biotech Stocks to Buy on the Dip: March 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

News Imagea month ago - The Motley Fool4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

News Image2 months ago - The Motley Fool2 Biotech Stocks to Buy Hand Over Fist in March

These stocks are worth buying in most months of the year.

News Image2 months ago - InvestorPlace3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success

With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.

News Image2 months ago - The Motley Fool4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

News Image2 months ago - Exelixis, Inc.Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
News Image2 months ago - Market News VideoFriday 2/23 Insider Buying Report: EXEL, HPP
News Image2 months ago - The Motley Fool2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

News Image2 months ago - FinancialNewsMediaAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

EXEL Links
Follow us for more